4 completed, 1 active not recruiting, 1 recruiting. 2 Not applicable, 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Heavy Water: new trials by email Literature Review of Heavy Water trials Research Report on Heavy Water
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Insulin Lowering on Lipogenesis Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70% - Hyperinsulinemia, Insulin Resistance | Phase 1 | Recruiting | Columbia University | 25 | 2026-07-01 | 2026-07-06 |
| Implementation and Validation of an Analytical Protocol for Measuring de Novo Lipogenesis in the Liver Using Stable Isotopes Deuterium oxide - De Novo Lipogenesis (DNL), Lipid Metabolism | Not applicable | Completed | KU Leuven | 10 | 2025-08-25 | 2026-08-03 |
| Immunology of Ebola Vaccine Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water - Ebola Virus Disease | Phase 2 | Active not recruiting | Emory University | 30 | 2024-08-06 | 2026-01-22 |
| Glycemic Effect of Diazoxide in NAFLD Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo - Hyperinsulinemia, Insulin Resistance | Phase 1 | Completed | Columbia University | 22 | 2023-08-01 | 2026-09-30 |
| Concurrent Assessment of Skeletal Muscle Mass and Synthesis/Breakdown in Old Age D3-Creatine, Deuterium Oxide, D3-3-methylhistidine - Sarcopenia, Muscle Atrophy | Completed | University of Nottingham | 37 | 2016-06-07 | 2020-03-25 | |
| Feasibility Study: Heavy Water Tissue Labeling Protocol Ulthera® System Treatment, Heavy Water - Skin Laxity | Not applicable | Completed | Ulthera, Inc | 2 | 2012-08-01 | 2017-12-11 |
Hyperinsulinism (2) · Insulin Resistance (2) · Non-alcoholic Fatty Liver Disease (2) · Prediabetic State (2) · Cutis Laxa (1) · Hemorrhagic Fever, Ebola (1) · Muscular Atrophy (1) · Obesity (1) · Sarcopenia (1)
Columbia University (2) · Emory University (1) · KU Leuven (1) · Ulthera, Inc (1) · University of Nottingham (1)
United States (4) · Belgium (1) · United Kingdom (1)
Joshua R Cook, MD, PhD (2) · Ali Ellebedy, PhD (1) · Gordon Sasaki, MD (1) · Nadine Rouphael, MD (1)
K12DK133995 (1), K23DK140614 (1)